Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01018420 · ClinicalTrials.gov registry record · Phase 1

Pharmacokinetic and Exploratory Electrocardiogram (ECG) Study

A Phase 1 study, sponsored by Mutual Pharmaceutical Company.

Completed
Registry status
Phase 1
Development phase
18
Enrollment target

NCT01018420 is a Phase 1 study that has completed, run by Mutual Pharmaceutical Company. The registered enrollment target is 18 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01018420, a Phase 1 study, has completed, sponsored by Mutual Pharmaceutical Company.

COMPLETED
Registry status
Phase 1
Development phase
18 participants
Enrollment target

Study Summary

This study will characterize the pharmacokinetics of colchicine after an oral dosing regimen of 4.8 mg over 6 hours. In addition it will compare the electrocardiogram (ECG) changes, if any, from this dosing regimen to that of a single dose of moxifloxacin 400 mg, a positive control for the corrected QT interval (QTc) prolongation.

Interventions

  • DRUG Colchicine
  • DRUG Moxifloxacin

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2007-11
Est. Completion 2008-01
Phase Phase 1

Sponsor

Mutual Pharmaceutical Company

27 total trials

What the Registry Record Tells You About NCT01018420

The ClinicalTrials.gov registry entry for NCT01018420 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mutual Pharmaceutical Company, which has 27 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Colchicine is the first listed.

NCT01018420 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01018420 about?

NCT01018420 is a clinical study titled "Pharmacokinetic and Exploratory Electrocardiogram (ECG) Study". This study will characterize the pharmacokinetics of colchicine after an oral dosing regimen of 4.8 mg over 6 hours. In addition it will compare the electrocardiogram (ECG) changes, if any, from this dosing regimen to that of a single dose of moxifloxacin 400 mg, a positive control for the corrected...

What is the current status of trial NCT01018420?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2007-11. Estimated completion is 2008-01.

What interventions are being tested in trial NCT01018420?

The interventions under investigation include: Colchicine (DRUG), Moxifloxacin (DRUG).

Who is sponsoring clinical trial NCT01018420?

This trial is sponsored by Mutual Pharmaceutical Company, which has 27 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.